Diferencias regionales en la mortalidad por cáncer de mama y cérvix en México entre 1979 y 2006

Abstract

The number of BC cases are increased gradually at the national level during the last three decades and high rates of CC mortality persist in marginalized areas.

Average years of life lost due to breast and cervical cancer and the association with the marginalization index in Mexico in 2000 and 2010

“…Although data shows that YLL due to cervical cancer declined considerably between 2000 and 2010, it is crucial to continue and to strengthen actions directed at education, prevention and continuous monitoring of breast cancer. Socioeconomic disparities in Mexico shown by the different marginalization indexes, confirm the need for interventions adjusted to multiple lifestyles and living conditions 7,27,28,29 . The trends in mortality from breast cancer, cervical cancer and YLL observed by this study are consistent with findings of studies in other Latin American countries where mortality rates due to breast cancer have surpassed cervical cancer 30,31 .…”

“…Historically, these two conditions have been the leading causes of death among women in this age group. The number of registered deaths due to breast cancer has showed an upward trend and surpassed cervical cancer in 2006 7,8 .…”

“…In Mexico, disparities in mortality rates still exist related to socioeconomic and geographic factors and the study of these variables is therefore important to obtain a better understanding of cervical cancer and breast cancer mortality 7,9,14,15 .…”

Epithelial–mesenchymal transition, proliferation, and angiogenesis in locally advanced cervical cancer treated with chemoradiotherapy

“…CC represents one of the leading causes of incidence and mortality due to cancer among women in Latin America 3, 4, 5. Regular screening using cervicovaginal cytology has decreased its frequency in developed countries.…”

“…Inconsistencies in the incidence/mortality ratio between countries with different economic resources are a consequence of marginal investment in screening programs and limited access to vaccines against human papilloma virus (HPV), which is associated with 90% of invasive neoplasms 2. Although information regarding the epidemiology of the disease in Latin America is limited, CC is known to be the second most common cause of cancer‐related death among women from Colombia and Mexico 3, 4, where locally advanced tumors (clinical stages IB2 to IVA according to the International Federation of Gynecology and Obstetrics [FIGO] staging classification) account for 60% of cases; lesions in early stages generally predominate in countries with greater wealth 3, 4, 5. Since the 1990s, chemoradiotherapy (CRT) has been implemented as the standard therapy for patients with locally advanced CC, and the 5‐year overall survival (OS) has increased by 12% 6.…”